Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine
Authors:
- Maureen DennehyMDMaureen Dennehy
- William BournWBWilliam Bourn
- Duncan SteeleDSDuncan Steele
- Anna-Lise WilliamsonAWAnna-Lise Williamson
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developmentsVaccine, 2003
- Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotavirusesVaccine, 2002
- The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvantVaccine, 2002
- CD4 T Cells Are the Only Lymphocytes Needed To Protect Mice against Rotavirus Shedding after Intranasal Immunization with a Chimeric VP6 Protein and the Adjuvant LT(R192G)Journal of Virology, 2002
- Recombinant BCG vaccinesVaccine, 2001
- Protective Efficacy of Rotavirus 2/6-Virus-Like Particles Combined with CT-E29H, a Detoxified Cholera Toxin AdjuvantViral Immunology, 2001
- Rotavirus Infection and Intussusception: A View from RetrospectMicrobiology and Immunology, 2000
- Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries1Prepared as a review for the Consensus Workshop on Rotavirus Vaccines for use in Developing Countries, Geneva, January 9–10, 1997. Sponsored by: The Global Programme for Vaccines, World Health Organization, The Children's Vaccine Initiative and the Centers for Disease Control and Prevention.1Vaccine, 1999
- Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particlesVaccine, 1999
- Rotavirus vaccines: success by reassortment?Science, 1994